Long-term imatinib therapy promotes bone formation in CML patients. [electronic resource]
Producer: 20080415Description: 2538-47 p. digitalISSN:- 0006-4971
- Adipogenesis -- drug effects
- Adult
- Aged
- Antineoplastic Agents -- pharmacology
- Benzamides
- Calcification, Physiologic -- drug effects
- Calcium -- blood
- Cell Proliferation -- drug effects
- Enzyme Activation -- drug effects
- Female
- Gene Expression Regulation, Leukemic -- drug effects
- Humans
- Imatinib Mesylate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Male
- Mesenchymal Stem Cells -- drug effects
- Middle Aged
- Organ Size -- drug effects
- Osteogenesis -- drug effects
- Phosphates -- blood
- Piperazines -- pharmacology
- Platelet-Derived Growth Factor -- pharmacology
- Proto-Oncogene Proteins c-akt -- metabolism
- Proto-Oncogene Proteins c-crk -- metabolism
- Pyrimidines -- pharmacology
- Time Factors
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.